[Salazosulfapyridine-induced eruption. Pustular erythroderma and pseudo-lymphomatous syndrome: 2 cases].
We report two observations of drug eruption due to salazosulfapyridine which occurred 15 to 21 days after introducing the molecule. The two patients were of Carabian origin and presented with fever, erythrodermia which became pustular and a pseudolymphomatous syndrome. Favourable outcome was observed 4 to 6 weeks later. The diagnosis of toxidermia was made based on the strong imputability of salazosulfapyridine in both cases. Severe immunoallergic reactions to this molecule have been described, including fatal cytolytic hepatitis and Lyell syndrome.
Gallais
V
V
Service de Dermatologie, Hôpital Bichat, Paris.
Grange
F
F
De Bandt
M
M
Crickx
B
B
Belaïch
S
S
D000328:Adult; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000150:complications / Q000209:etiology* / Q000473:pathology; D004802:Eosinophilia / Q000150:complications; D005260:Female; D006801:Humans; D006965:Hyperplasia; D008198:Lymph Nodes / Q000473:pathology; D008223:Lymphoma / Q000175:diagnosis; D008875:Middle Aged; D012460:Sulfasalazine / Q000009:adverse effects*
D012460:Sulfasalazine
Toxidermie à la salazosulfapyridine. Erythrodermie pustuleuse et syndrome pseudolymphomateux: 2 observations.